Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
Marine Drugs · 2026
DOI: 10.3390/md24030090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2026. Verfasst von Xinglong Dai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China…. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Pulmonary Disease, Chronic Obstructive, Anti-Inflammatory Agents, Aquatic Organisms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, Shandong Provincial Key Research and Development Program, Special funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology.
Themen: COPD
Abstract (Originalsprache)
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory respiratory disorder with a globally increasing prevalence. Current therapeutic strategies are limited by drug resistance and safety concerns. Studies suggest that inhibiting the secretion of inflammatory cytokines represents a promising approach for COPD treatment. Phosphodiesterase-4 (PDE4) inhibitors have emerged as potent anti-inflammatory agents for respiratory diseases. In this study, we integrated a marine-derived natural product with computer-aided drug design to develop 32 novel PDE4 inhibitors. Compound B7 exhibited potent PDE4 inhibitory activity and a favorable safety profile. In rat model of COPD, B7 significantly reduced inflammatory cell infiltration and cytokine levels, ameliorated pathological changes in the lung, decreased the percentage of goblet cell positivity, and reduced expiratory resistance. Furthermore, in vitro mechanistic studies revealed that B7 exerts its anti-inflammatory effects by activating the cAMP-PKA-CREB signaling pathway and suppressing the NF-κB pathway in RAW264.7 cells. In conclusion, B7 demonstrates potential as a safe and effective PDE4-targeted candidate for the treatment of COPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao 266003, China.
ORCID-Profile: Jianchun Zhao
Förderung
- National Nature Science Foundation of China
- Shandong Provincial Key Research and Development Program
- Special funds of Shandong Province for Qingdao National Laboratory of Marine Science and Technology
- Shandong Province for Qingdao National Laboratory of Marine Science and Technology
Zitieren
APA
Dai, X., Hao, J., Zhang, Y., Yang, Y., Meng, W., Lu, F., Zhao, J., Du, G., Wan, S., & Hao, J. (2026). Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Marine Drugs. https://doi.org/10.3390/md24030090
Vancouver
Dai X, Hao J, Zhang Y, Yang Y, Meng W, Lu F, et al. Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Marine Drugs. 2026. doi:10.3390/md24030090
BibTeX
@article{Dai2026,
author = {Dai, Xinglong and Hao, Jie and Zhang, Yan and Yang, Yaping and Meng, Wanli and Lu, Fang and Zhao, Jianchun and Du, Guanhua and Wan, Shengbiao and Hao, Jiejie},
title = {Discovery of Marine-Inspired Guanidine-Based PDE4 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease},
journal = {Marine Drugs},
year = {2026},
doi = {10.3390/md24030090}
}
EUVIMED